News


December 10, 2015

Zafgen’s Beloranib IND gets complete clinical hold after second death

Zafgen, a Boston-based biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders, has received verbal notice from the FDA that its beloranib investigational new drug (IND) application has been placed on complete clinical hold, affecting the ongoing open label extension (OLE) portion of the pivotal…


November 16, 2015

ORI Case Summary – Potti, Anil

Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Anil Potti, M.D., Duke University School of Medicine:  Based on the reports of investigations conducted by Duke University School of Medicine (Duke) and additional analysis conducted by ORI in its oversight review, ORI found that Dr….


December 16, 2014

Debarment of Two Investigators

The HHS Office of Research Integrity (ORI) recently announced the debarment of two investigators who are prohibited from receiving government funding and serving in advisory capacities for three-year periods. Igor Dzhura, a former senior research associate in the Department of Biomedical Engineering at Vanderbilt University, “engaged in research misconduct by providing falsified and/or fabricated data…


December 15, 2014

Postdoctoral Fellow Engaged in Misconduct

ORI also found that Kaushik Deb, a former postdoctoral fellow at the University of Missouri-Columbia, engaged in misconduct in connection with a paper that was retracted in 2007, a year after it was published. ORI said Deb “intentionally, knowingly, and recklessly fabricated and falsified data” in a paper, “Cdx2 gene expression and trophectoderm lineage specification…


August 29, 2014

ORI Case Summary – Falsified survival times of mice

Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Jun Fu, Ph.D., University of Texas MD Anderson Cancer Center: Based on the Respondent’s admission, the report of an inquiry conducted by the University of Texas MD Anderson Cancer Center (MDACC), and analysis conducted by ORI in…


July 29, 2014

ORI Case Summary – Falsified data in publications

Case Summary: Zou, Zhihua DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct AGENCY:  Office of the Secretary, HHS. ACTION:  Notice. SUMMARY:  Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Zhihua Zou, Ph.D., Harvard Medical School and Fred Hutchinson…


April 1, 2014

Pre-April 2014 Articles

February 2014 ORI Case Summary – Falsified data for increased subject enrollment December 2013 ORI Case Summary – Fabricated data in publications November 2013 FDA Warning Letter – Failure to ensure adherence to regulations and subject safety February 2013 ORI Case Summary – Falsified data in publications and abstracts January 2013 FDA Warning Letter –…